Manish K. Aghi MD, PhD
Associate Professor in Residence of Neurological Surgery
Co-Director, Center for Minimally Invasive Skull Base Surgery
Dr. Aghi is a neurosurgeon-scientist specializing in adult brain tumors. He is experienced in the surgical treatment of glioneuronal neoplasms, meningiomas, and pituitary tumors. He has experience with minimally invasive endoscopic approaches to the anterior skull base, and intraoperative mapping of brain function to optimize tumor resection. Dr. Aghi has extensive basic science research interests, including glioma angiogenesis and the use of oncolytic viruses to treat glioblastoma. Read about Dr. Aghi's basic science research laboratory in the UCSF Brain Tumor Research Center (BTRC) here.
Education, Training, and Previous Positions
- 1993: BS, MS, Stanford University
- 2000: MD, PhD, Harvard Medical School
- 2000-2007: Residency, Neurological Surgery, Massachusetts General Hospital
- 2007: Instructor, Department of Neurological Surgery, Massachusetts General Hospital and Harvard Medical School
- 2008-2012: Assistant Professor in Residence, Department of Neurological Surgery, UCSF
2012-present: Associate Professor in Residence, Department of Neurological Surgery, UCSF
Selected Professional Memberships and Appointments
- Society for Neuro-Oncology (SNO)
- Pituitary Network Association (PNA)
International Society of Pituitary Surgeons (ISPS)
- American Association of Neurological Surgeons (AANS)
- Congress of Neurological Surgeons (CNS)
- AANS and CNS, Joint Section for Tumors
Selected Honors and Awards
- 2004: Preuss Resident Research Award, American Association of Neurologic Surgeons and Congress of Neurological Surgeons
- 2005: Ronald L. Bittner Award, American Association of Neurologic Surgeons (AANS)
- 2005: William Scoville Resident Research Award, New England Neurosurgery meeting
- 2005: Congress of Neurologic Surgeons (CNS) Resident Research Award
- 2005: American Academy of Neurologic Surgeons Resident Research Award
- 2006: Mahaley Award, American Association of Neurologic Surgeons
- 2006: Integra Foundation Award, Congress of Neurologic Surgeons
- 2007: Synthes Skull Base Award, Congress of Neurologic Surgeons
2009: American Brain Tumor Association (ABTA) Young Investigator Award, Congress of Neurologic Surgeons
Selected Recent Publications
Hu YL, Jahangiri A, De Lay M, Aghi MK. Hypoxia-induced tumor cell autophagy mediates resistance to anti-angiogenic therapy. Autophagy, In Press.
De Lay M, Jahangiri A, Carbonell WS, Hu Y-L, Tsao S, Tom MW, Paquette J, Tokuyasu TA, Aghi MK. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to anti-angiogenic therapy. Clin Cancer Res, In Press.
Hu YL, Jahangiri A, DeLay M, Aghi MK. Tumor cell autophagy as an adaptive response mediating resistance to treatments like anti-angiogenic therapy. Cancer Research, In Press.
Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. Neurosurgical management and prognosis of patients with glioblastoma that progress during bevacizumab treatment. Neurosurgery 2012;70:361-70.
Jahangiri A, Lamborn KR, Blevins L, Kunwar S, Aghi MK. Factors associated with delay to pituitary adenoma diagnosis in patients with visual loss. J Neurosurg 2012;116(2):283-9.
Aghi MK, Vogelbaum MA, Jost S, Heimberger AB, Sampson JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM. Application of novel response/progression measures for surgically delivered therapies for gliomas. Neurosurgery 2012;70(1):234-43.
Hu YL, DeLay M, Rose SD, Carbonell WS, Aghi MK. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to anti-angiogenic treatment in glioblastoma. Cancer Res 2012;72:1-11.
Potts MB, Jahangiri A, Lamborn KR, Blevins LS, Kunwar S, Aghi MK. Suprasellar Rathke's Cleft Cysts: Clinical presentation and treatment outcomes. Neurosurgery 2011;69:1058-69.
Kaur G, Bloch O, Jian BJ, Kaur R, Sughrue ME, Aghi MK, McDermott MW, Berger MS, Chang SM, Parsa AT. A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival. Journal of Neurosurgery 2011;115:754-759.
Jahangiri A, Aghi MK. Biomarkers predicting tumor response and evasion to anti-angiogenic therapy. Biochim Biophys Acta 2011;1825:86-100.
Sughrue ME, Chang EF, Gabriel RA, Aghi MK, Blevins LS. Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary 2011;14(3):276-83.
Rose SD, Aghi MK. Mechanisms of evasion to antiangiogenic therapy in glioblastoma. Clin Neurosurg 2010;57:123-8.
Clark AJ, Butowski NA, Chang SM, Prados MD, Clarke J, Polley MY, Sughrue ME, McDermott MW, Parsa AT, Berger MS, Aghi MK. Impact of bevacizumab chemotherapy on craniotomy wound healing. J Neurosurg 2011;114(6):1609-16.
Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas. J Neurosurg 2011;114(5):1369-79.
Tate MC, Jahangiri A, Blevins L, Kunwar S, Aghi MK. Infected Rathke cleft cysts: distinguishing factors and factors predicting recurrence. Neurosurgery 2010;67(3):762-9.
Sughrue ME, Aghi MK. Reconstruction of dural defects of the endonasal skull base. Neurosurg Clin N Am 2010;21(4):637-41, vi.
Yang I, Aghi MK. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol 2009;6(11):648-57.
Rose SD, Aghi MK. Mechanisms of evasion to antiangiogenic therapy in glioblastoma. Clin Neurosurg. 2010;57:123-8.Tate MC, Aghi MK. Biology of angiogenesis and invasion in glioma. Neurotherapeutics 2009; 6: 447-457.
Aghi MK, Blevins LS Jr. Recent advances in the treatment of acromegaly. Curr Opin Endocrinol Diabetes Obes 2009; 16: 304-307.
Aghi MK, Batchelor TT, Louis DN, Barker FG, Curry WT. Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. Journal of Neuro-oncology 2009; 93: 115-120.
Aghi MK, Petit J, Chapman P, Loeffler J, Klibanski A, Biller BMK, Swearingen B. Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery. Clin Neurosurg 2009; 55: 141-144.
Aghi MK, Carter BS, Cosgrove GR, Ojemann RS, Amin-Hanjani S, Martuza RL, Curry WT, Barker FG. Long-term recurrence rates of atypical meningiomas after gross total resection without or with postoperative adjuvant radiation. Neurosurgery 2009; 64: 56-60.
Aghi MK, Chiocca EA. Phase Ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther 2009; 17: 8-9.
Aghi MK, Liu TC, Rabkin S, Martuza RL. Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus. Mol Ther 2008; 17: 51-56.
Aghi MK. Management of recurrent and refractory Cushing disease. Nat Clin Pract Endocrin Metab 2008;4(10):560-8.
Aghi M, Visted T, Depinho RA, Chiocca EA.Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 2008;27(30):4249-54.
Aghi MK, Eskandar EN, Carter BS, Curry WT Jr, Barker FG 2nd. Increased prevalence of obesity and obesity-related postoperative complications in male meningioma patients. Clin Neurosurg 2007;54:236-40.
Aghi M, Rabkin SD, Martuza RL. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res 2007;67(2):440-4.
Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.J Natl Cancer Inst 2006;98(1):38-50.
Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 2006;66(18):9054-64.
Aghi M, Kluwe L, Webster MT, Jacoby LB, Barker FG 2nd, Ojemann RG, Mautner VF, MacCollin M. Unilateral vestibular schwannoma with other NF2-related tumors: clinical and molecular study of a unique phenotype. J Neurosurg 2006;104(2):201-7.
Aghi M, Chiocca EA. Gene therapy for glioblastoma. Neurosurg Focus 2006;20(4):E18.
Aghi M, Barker FG 2nd. Benign adult brain tumors: an evidence-based medicine review. Prog Neurol Surg 2006;19:80-96.
Aghi M, Kiehl TR, Brisman JL. Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature [Review]. J Neurooncol 2005;75(2):149-55.
Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005;11(24 Pt 1):8600-5.
Aghi M, Chiocca EA. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther 2005;12(6):994-1005.
Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005;24(52):7802-16.
Aghi M, Rabkin S. Viral vectors as therapeutic agents for glioblastoma. Curr Opin Mol Ther 2005;7(5):419-30.
Hoh BL, Aghi M, Pryor JC, Ogilvy CS. Heparin-induced thrombocytopenia Type II in subarachnoid hemorrhage patients: incidence and complications. Neurosurgery 2005;57(2):243-8; discussion 243-8.
Aghi M, Coumans JV, Brisman JL. Subarachnoid hematoma, hydrocephalus, and aseptic meningitis resulting from a high cervical myelogram. J Spinal Disord Tech 2004;17(4):348-51. Erratum in: J Spinal Disord Tech 2005;18(2):207.
Aghi M, Chiocca EA. Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review. Cancer Invest 2003;21(2):278-92.
Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000;2(3):148-64.
Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res 1999;59(16):3861-5.
Aghi M, Kramm CM, Breakefield XO. Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo. J Natl Cancer Inst 1999;91(14):1233-41.
Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998;90(5):370-80.